{
  "chunk_id": "V_ii_3_D_53",
  "content": "/>\nV.ii.3.D.5.a\n.\nEvaluating Malignant Neoplasms and Associated Impairments\nUse the table below to determine whether a symptom or condition associated with an active malignant neoplasm may be separately evaluated during the period in which a 100-percent evaluation is warranted for the active malignant neoplasm.\nIf the condition is a ...\nThen ...\npurely symptomatic complaint arising from the malignant neoplasm\ndo not assign a separate evaluation.\nsymptom arising from treatment for the malignant neoplasm\ndo not assign a separate evaluation.\ndiagnosed disability deemed to be caused by or related to the malignant neoplasm\napply\n38 CFR 4.14\nto determine whether the symptoms of the diagnosed disability are considered in the 100-percent evaluation for the malignant neoplasm\nreview the evaluation criteria for both conditions and other applicable provisions to determine whether separate evaluations are allowable, and\nif the pyramiding rule in\n38 CFR 4.14\nhas not been violated and separate evaluations are otherwise allowable, assign a separate evaluation.\nNote\n:  When the DC for the active malignancy is directive as to how to evaluate residuals of the cancer, conditions or symptoms that\nwould be rated as residuals should not be assigned a separate evaluation during the pendency of the 100-percent evaluation for the active malignancy, and\nwould not be rated as residuals may be granted separately and concurrently with the 100-percent evaluation.\nmetastatic malignant neoplasm affecting a different body system than is affected by the primary SC neoplasm\nassign a separate evaluation.\nNote\n:  For the purpose of determining entitlement to SMC at the statutory housebound rate under\n38 CFR 3.350(i)(1)\n, carcinoma that has metastasized and involves two different body systems would generally be considered separate and distinct.  The fact that there is an etiological relationship does not preclude considering the impact and effects as separate and distinct.\nmetastatic malignant neoplasm affecting the same body system as is affected by the primary SC neoplasm\ndo not assign a separate evaluation.\nNote\n:  This guidance is applicable when language within a particular DC refers to\nmalignant neoplasms\nin plural.\nNote\n:  If doubt arises as to the medical cause or association of any symptoms or diagnosis, a medical opinion should be requested for clarification.\nReferences\n:  For more information on\nassignment of separate evaluations for individual findings, see\nM21-1, Part V, Subpart ii, 3.D.2.b\n, and\nentitlement to SMC based on housebound status, see\nM21-1, Part VIII, Subpart iv, 4.A.10\n.",
  "title": "M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities",
  "citation": "Part V, Subpart ii, Chapter 3, Section D",
  "source_url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities",
  "updated": "",
  "scraped_at": "2025-06-16T22:42:38.373209",
  "tags": [
    "m21-1"
  ]
}